 |
|
Multiple Sclerosis That Is Progressive From the Time of Onset
Clinical Characteristics and Progression of Disability
P. B. Andersson, MBChB, DPhil;
E. Waubant, MD;
L. Gee, MPH;
D. E. Goodkin, MD
Arch Neurol. 1999;56:1138-1142.
Objective To use the new consensus definitions of primary progressive multiple sclerosis (PPMS) and progressive relapsing multiple sclerosis (PRMS) to report the demographic, clinical, and natural history characteristics of multiple sclerosis (MS) that is progressive from the time of onset.
Design Retrospective study by database/chart review and telephone interview.
Setting Multiple sclerosis clinic at a university teaching hospital.
Patients Eighty-three patients (prevalence, 6.9%) with PPMS and 12 patients (prevalence, 1.0%) with PRMS were studied.
Results Fifty-nine percent of the patients with PPMS (n=49) and 67% of the patients with PRMS (n=8) were women. Mean±SD ages at the time of onset were 41.2±10.5 and 38.0±7.3 years, respectively; mean disease duration was 14.2±8.8 and 12.2±6.5 years, respectively. The initial symptoms involved leg weakness in 94% of the patients with PPMS (n=78) and 100% of the patients with PRMS (n=12). For the PPMS cohort, a syndrome consistent with isolated myelopathy was found in 36% of patients (n=30) and arm weakness without leg weakness did not occur. Mean±SEM time of progression to a score of 6.0 on the Expanded Disability Status Scale was 10.2±1.0 years for patients with PPMS and 10.9±2.6 years for patients with PRMS.
Conclusions The clinical characteristics and disability progression of these MS subtypes were indistinguishable, with the exception of 1 or 2 relapses in patients with PRMS that occurred 8 months to 9 years after the onset of symptoms. We see little reason to consider PPMS and PRMS separate clinical entities; however, whether they can be better distinguished by radiological, histopathological, or immunological markers of disease activity remains unknown.
From the Mount Zion Multiple Sclerosis Center (Drs Andersson, Waubant, and Goodkin) and the Department of Biostatistics and Epidemiology (Ms Gee), University of California, San Francisco, School of Medicine.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(9):1169-1171.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
Kremenchutzky et al.
Brain 2006;129:584-594.
ABSTRACT
| FULL TEXT
Natural history of multiple sclerosis: a unifying concept
Confavreux and Vukusic
Brain 2006;129:606-616.
ABSTRACT
| FULL TEXT
The natural history of primary progressive MS in British Columbia, Canada
Tremlett et al.
Neurology 2005;65:1919-1923.
ABSTRACT
| FULL TEXT
Multiple sclerosis: diagnosis and the management of acute relapses
Leary et al.
Postgrad. Med. J. 2005;81:302-308.
ABSTRACT
| FULL TEXT
Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging
Oh et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:1281-1286.
ABSTRACT
| FULL TEXT
Clinical characteristics of progressive relapsing multiple sclerosis
Tullman et al.
Mult Scler 2004;10:451-454.
ABSTRACT
Natural history of primary progressive multiple sclerosis
Ebers
Mult Scler 2004;10:S8-S15.
ABSTRACT
Mitoxantrone as a potential therapy for primary progressive multiple sclerosis
Stuve et al.
Mult Scler 2004;10:S58-S61.
ABSTRACT
Natural history of primary progressive multiple sclerosis
Ebers
Mult Scler 2004;10:S8-S15.
ABSTRACT
Mitoxantrone as a potential therapy for primary progressive multiple sclerosis
Stuve et al.
Mult Scler 2004;10:S58-S61.
ABSTRACT
Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?
Rudick
Mult Scler 2003;9:210-212.
In search of a disease marker: the cytokine profile of primary progressive multiple sclerosis
Neuhaus and Hartung
Mult Scler 2001;7:143-144.
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux et al.
NEJM 2000;343:1430-1438.
ABSTRACT
| FULL TEXT
Chronic Fatigue Syndrome: Sociodemographic Subtypes in A Community-Based Sample
Jason et al.
Eval Health Prof 2000;23:243-263.
ABSTRACT
|
